Figure 2: Prophylactic and therapeutic efficacy of 3E1 mAb in mice.
From: Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses
(a,b) Prophylactic efficacy of 3E1 mAb against a lethal challenge with the A/Sichuan/09/2009(H1N1) virus (a) or A/CK/NX/S6/2014(H5N6) virus (b). The weight loss (left) and survival curves (right) of mice treated with 30, 10, 3 or 1 mg kg−1 of 3E1 mAb or PBS buffer 24 h before lethal challenge by an intranasal inoculation with the H1-SC09 or H5-NX14 virus (at day 0) are shown. (c,d) Therapeutic efficacy of 3E1 mAb against a lethal challenge with the A/Sichuan/09/2009(H1N1) (c) or A/CK/NX/S6/2014(H5N6) virus (d). The weight loss (left) and survival curves (right) of mice treated with PBS buffer (at day 1) or 20 mg kg−1 of 3E1 mAb right after or 1, 2, 3 days after lethal challenge by an intranasal inoculation with the H1-SC09 or H5-NX14 virus (at day 0) are shown. Error bars represent mean±s.d. Data represent a representative experiment from three independent experiments.
